secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105159
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Q2 revenue $63.7M; cash $205.1M; STRO-004 IND on track for H2 2025
------------------------------------------------------------------------

- Q2 revenue $63.7M, up 148% YoY, driven by Astellas collaboration and Ipsen deferred revenue recognition.
- Cash, equivalents and marketable securities $205.1M; cash runway into early 2027.
- R&D and G&A expenses $48.7M (down 35% YoY); restructuring costs $18.4M from luvelta deprioritization.
- STRO-004 FIH trial on track for H2 2025; STRO-006 clinical in 2026; dual-payload ADC IND filing in 2027.
- Astellas milestone triggered $7.5M payment; Ipsen terminates STRO-003; Greg Chow appointed CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017025105159/0000950170-25-105159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017025105159/stro-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer